★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Biopharma Space Showing Signs of a Burgeoning Buying Spree M&A activity is picking up among pharmaceutical firms with large cash balances. Pfizer and Amgen have each closed a multi-billion…McAlinden Research PartnersAugust 9, 2022
⚑ Joe Mac's ViewpointsCommoditiesMarketsMonetary PolicyReal Estate & Construction The FX Timebomb A relentless, yearlong rise in the relative value of the US Dollar recently sent the greenback to multi-decade highs versus…McAlinden Research PartnersAugust 8, 2022
★ Daily Intelligence Briefings (DIBs)CommoditiesFinanceMarketsTechnology BTC Rebound Set to Revitalize Crypto Miners Bent by Bear Market Pressure After several downward revisions to Bitcoin's (BTC) mining difficulty, computing power provided to the network appears to be rising again.…McAlinden Research PartnersAugust 8, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerⓁ CybersecurityMarketsTechnology Cyberthreats Resistant to Economic Headwinds, Cybersecurity Spending Will Have to Keep Up The number of cyberattacks are on the rise, but the average cost of each attack is increasing even faster. Billions of…McAlinden Research PartnersJuly 22, 2022
★ Daily Intelligence Briefings (DIBs)FinanceMarkets Bank Profits Broadly Lower in Q2 as Loan Loss Reserves Run out, Investment Banking Stalls US banks' second quarter results helped to map out an uncertain future for the financial sector. Trading revenues rose but…McAlinden Research PartnersJuly 19, 2022
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareMarketsPolitics & Policy Battered Psychedelics Stocks Rebound on Wave of Scientific, Legislative Support Psychedelic medicine, focused on alternative mental health therapies that utilize drugs like LSD, MDMA and psilocybin, is becoming increasingly popular…McAlinden Research PartnersJuly 18, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Major Patent Cliff Closes in on Big Pharma, Bargain-Priced Acquisitions Could Bolster Their Pipelines Last year marked one of the least active years for biopharma merger and acquisition (M&A) activity in a decade. The first…McAlinden Research PartnersJuly 14, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets CRISPR Closing in on First US Product Launch, Latest Data Shows Treatment 100% Effective After Three Years A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…McAlinden Research PartnersJuly 11, 2022
⚑ Joe Mac's Viewpoints⦁ Theme TrackerⓁ Aerospace & DefenseⓁ CybersecurityⓁ PharmaceuticalsⓁ SolarⓁ SteelⓁ Travel & LeisureMarketsMonetary Policy MRP’s 2022 Mid-Year Review 2021 marked another successful year for MRP’s themes, as 16 of 21 themes we closed throughout the year outperformed the…McAlinden Research PartnersJuly 6, 2022
★ Daily Intelligence Briefings (DIBs)FinanceMarkets Stress Test Results Could Spur Optimism in Financial Sector, But Recession Fears Still Loom Large The Federal Reserve will publish results from their annual stress tests of major US financial institutions today after the close. Based on those,…McAlinden Research PartnersJune 23, 2022